ReviewInternational journal of molecular medicine2025
New advances of nanozymes for the diagnosis and treatment of digestive system diseases (Review).
Review in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Microcystin-LR-Induced Oxidative Stress, Transcriptome Changes, Intestinal Microbiota, and Histopathology inAnimals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the significant progress that has been made in the diagnosis and treatment of digestive system diseases, these conditions continue to pose a serious public health concern worldwide. There is an ongoing need for strategies that are precise, efficient and minimally invasive. Nanozymes, engineered nanomaterials that exhibit catalytic functions, have attracted considerable interest in this context. However, clinical application of nanozymes remains limited primarily due to their diversity, targetability, biocompatibility and early‑stage clinical translation. The present review presented a comprehensive analysis of nanozymes in digestive system diseases. The main enzyme‑like activities of nanozymes are summarized to guide further material selection and characteristic exploration. Preclinical applications are highlighted with mechanisms and theranostic effects discussed alongside their potential limitations. Emerging combination therapies, including photodynamic therapy, sonodynamic therapy and biotherapy, are reviewed. Finally, the current challenges of nanozymes and possible future developments are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.